Personalized immunotherapy strategies aim to improve outcomes for frail myeloma patients
NCT ID NCT07649525
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. After six months of standard treatment with daratumumab, lenalidomide, and dexamethasone, participants are assigned to different immunotherapy combinations based on their fitness and how well their cancer responded. The goal is to find out which treatment strategy works best for different patient groups, focusing on survival and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daratumumab, lenalidomide, dexamethasone, teclistamab, talquetamab
What this could lead to
If successful, this trial could identify better treatment strategies for older or frailer myeloma patients, potentially improving survival and quality of life without the need for a stem cell transplant.
What could go wrong
This is a large phase 3 trial, but results depend on how well patients tolerate the drug combinations. Side effects from immunotherapy and standard drugs may limit benefits for some participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bristol Haematology and Oncology Centre
Bristol, BS2 8ED, United Kingdom
Contact Email: •••••@•••••
-
Eastbourne District General Hospital
Eastbourne, BN21 2UD, United Kingdom
Contact Email: •••••@•••••
-
St James University Hospital
Leeds, LS9 7TF, United Kingdom
Contact Email: •••••@•••••
-
The Royal Marsden Hospital
London, SM2 5PT, United Kingdom
Contact Email: •••••@•••••